What viscosupplementation does in an arthritic knee

Think of the fluid inside a healthy knee joint as a thick, shock-absorbing gel — closer to egg white than water. That gel is largely made up of hyaluronic acid (HA), a long-chain molecule that gives synovial fluid its capacity to cushion cartilage surfaces under load and keep them gliding smoothly against each other. In osteoarthritis (OA), HA molecules break down: concentration falls and chain lengths shorten, leaving the joint fluid thinner and less effective — more like water than gel. The result is increased friction, greater mechanical stress on cartilage, and a joint environment that is harder to protect.

A viscosupplementation injection introduces pharmaceutical-grade HA directly into the joint space, with the aim of restoring those viscoelastic properties and reducing the mechanical load that damaged cartilage has to bear. The word 'viscosupplementation' simply means supplementing the viscosity of the fluid — replacing what OA has degraded.

There is a secondary dimension beyond pure lubrication. HA appears to interact with receptors on cells within the joint lining, and some evidence suggests it may help reduce the concentration of inflammatory mediators in the synovial fluid. This biological activity is thought to contribute to the clinical benefit, though it remains a secondary and less-established rationale rather than the primary licensed indication.

One observation that points toward these downstream effects: the injected HA clears from the joint within days, yet pain relief in many patients persists for months. That mismatch suggests the benefit is not simply mechanical top-up, but involves changes in how the joint tissue behaves after the injection.

The patient profile most likely to respond

Not everyone with knee OA is equally likely to benefit, and understanding that distinction matters as much as the evidence on efficacy.

The patient profile that tends to respond best shares several characteristics:

• Mild-to-moderate OA — specifically Kellgren-Lawrence (KL) Grades I to III on imaging, where some cartilage remains intact
• Younger age and lower BMI, both of which appear to be associated with more consistent improvement
• Incomplete relief from first-line care — those who have already tried physiotherapy, exercise programmes, and oral analgesics or NSAIDs but have not found adequate symptom control
• A preference or clinical need to delay or avoid surgery, or an inability to tolerate long-term NSAID use

For patients with end-stage 'bone-on-bone' disease (KL Grade IV), HA injections are broadly not indicated — at that point, the joint has too little remaining cartilage for the treatment to address meaningfully. It is also worth noting that many of the clinical trials underpinning HA's efficacy data specifically excluded KL Grade IV patients, which means the published results may overestimate how well the treatment performs across the full spectrum of OA severity.

Individual response remains variable even within the ideal patient profile. A meaningful minority see limited or no benefit, and current evidence does not fully explain who those patients will be. A specialist assessment — rather than imaging alone — is the appropriate starting point for gauging likely suitability.

What the clinical evidence actually shows

Multiple large, well-designed studies now support the clinical case for HA injections — and the findings are more consistent than the debate in guidelines might suggest.

The clearest signal comes from a 2024 systematic review and meta-analysis by Migliorini and colleagues, drawing on 3,851 patients across randomised controlled trials — the highest level of clinical evidence. It found statistically significant reductions in WOMAC pain and stiffness scores at weeks 2–4, and in VAS pain at rest at weeks 5–8, compared with placebo. A separate network meta-analysis across 43 RCTs and 5,554 patients (Han et al, cited in Cao 2026) reported a standardised mean difference of 0.94 for pain reduction versus placebo — a meaningful effect size — alongside a low rate of adverse events. A 2025 systematic review by Bruyère and colleagues adds that these benefits can be sustained with repeated injection courses over time.

The honest complication is the placebo effect. Injecting any substance into a painful joint — including saline — produces measurable pain relief in a proportion of patients. This makes isolating the 'true' pharmacological contribution of HA genuinely difficult, and it is the central reason why the clinical debate persists even as the statistical evidence accumulates. The magnitude of benefit attributable specifically to HA, beyond the therapeutic ritual of the injection itself, remains contested.

Separately, there is emerging but unconfirmed interest in whether HA might slow structural joint deterioration — some formulations have been associated with reduced joint-space narrowing in observational data, but this has not been conclusively established in controlled trials.

Taken together, the weight of high-quality systematic evidence tilts toward efficacy. The debate is real, but it is a debate about the size of the effect — not about whether an effect exists.

How long relief typically lasts and when to repeat

The timing of benefit follows a fairly predictable arc, and setting the right expectation at the outset matters — particularly because HA works quite differently from a corticosteroid.

In the first two weeks after injection, most patients notice little change. Relief typically begins between two and six weeks post-injection as the biological and mechanical effects build. The peak window is generally around eight to twelve weeks, when pain reduction and functional improvement are at their most pronounced. For most patients, that benefit can be sustained for approximately six months before it gradually wanes — at which point a repeat course becomes a reasonable option.

Repeat injections are not a step backwards. A 2025 review of repeated HA injection data found that successive courses maintain symptom control without introducing additional safety risk, supporting their use as a long-term management strategy for patients who respond well.

For those approaching but not yet at surgical readiness, there is a practical dimension worth noting. Health-economic and claims-database analyses suggest that HA may delay total knee replacement by approximately six to nine months. This is not a guaranteed outcome — individual response varies — but it is a meaningful interval for a patient who is managing symptoms while waiting for the right clinical moment to consider surgery.

Patients who have previously had corticosteroid injections and found them effective within days should be aware that HA operates on a different timescale. The slower onset is not a sign that the treatment has failed; it reflects a different mechanism of action entirely.

HA vs corticosteroids, and does the product type matter

Choosing between HA and a corticosteroid injection is less a question of which is better and more a question of when the patient needs relief — and for how long.

Corticosteroids act faster. Studies consistently show they outperform HA in the first month, making them the more appropriate choice when rapid symptom control is the priority — before a significant event, for instance, or to break an acute pain cycle. HA, by contrast, provides superior symptom control at the six-month mark, based on published comparative data. For patients focused on sustained medium-term benefit rather than immediate relief, the evidence favours HA.

Neither option is universally superior. The practical decision turns on the individual's goals and timeline, which is why this is best approached as a shared conversation between patient and clinician rather than a protocol.

Does the formulation make a difference?

Not all HA products are equivalent. High-molecular-weight (HMW) formulations are generally more effective at lubricating the joint and reducing pain than low-molecular-weight (LMW) alternatives in head-to-head comparisons. From a practical standpoint, a single HMW injection appears comparable to a course of three weekly LMW injections for both pain and function at two and six months — a relevant convenience consideration for some patients.

Formulation is worth discussing at consultation, but it is a secondary variable. The more meaningful decision is whether HA's medium-term profile is the right fit for the individual patient's situation.

Where HA fits in the treatment pathway for knee OA

Across the management of knee OA, treatment typically follows a staged progression: optimise conservative care first (exercise, weight management, physiotherapy, oral analgesics and NSAIDs), consider injection support when those measures have been exhausted, and reserve surgery for patients who have not responded adequately to non-operative options. HA sits firmly in that middle stage — a second-line intervention for patients who have moved beyond first-line care but are not yet at surgical readiness.

Where it becomes complicated is the guideline landscape. In 2013, the American Academy of Orthopaedic Surgeons (AAOS) issued a recommendation against HA, and real-world utilisation data show that prescribing fell measurably in the years that followed. Yet in 2019, OARSI endorsed HA, and the VA-DoD guidelines followed with endorsement in 2020 — after which that decline in use stabilised. The AAOS's 2021 update retained a cautious position. Different bodies reviewed substantially the same evidence and reached different conclusions, which is itself a meaningful signal: the debate reflects genuine uncertainty about the size of the benefit, not an absence of evidence.

It is also worth being clear about what HA does not do. It does not reverse structural OA or regenerate cartilage; it is a symptom-management strategy that may extend the functional window before surgery becomes necessary.

Whether HA is appropriate at a given patient's stage depends on individual factors — disease severity, treatment history, and personal goals — that require a specialist assessment to evaluate properly.